<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">Shengmai is composed of red ginseng, ophiopogon japonicas, and schisandra chinensis [
 <xref ref-type="bibr" rid="CR64">64</xref>]. Shengmai has often been used clinically to treat cardiovascular and cerebrovascular diseases. When Shengmai combined with conventional treatment in systemic inflammatory response syndrome, it can significantly increase the plasma prostacyclin (PGI2) and PGI2/TXA2, reduce the atrial natriuretic peptide (ANP) and endothelin (ET) level and improve breathing and vascular microcirculation. Shengmai plays a protective role in various organs [
 <xref ref-type="bibr" rid="CR64">64</xref>]. One study observed the clinical effect of Shengmai on elderly patients with pulmonary infections and multiple organ failure. The results showed that adding Shengmai can significantly improve the cure rate of patients (treatment group: 83.9%, oral Shengmai powder control group: 69.6%, control group: 52.2%), and shorten the improvement time and cure rate of multiple organ failure. Shengmai has the characteristics of rapid action and a remarkable curative effect [
 <xref ref-type="bibr" rid="CR65">65</xref>]. Schisandra chinensis in Shengmai can increase the weight of spleen and lymph nodes in immunosuppressed mice caused by cyclophosphamide, increase the total volume of splenic white nucleus pulposus lymph node cortex, and enhance the body's immune function [
 <xref ref-type="bibr" rid="CR66">66</xref>].
</p>
